This site is intended for U.S. healthcare professionals.
Menu
Close
About
About
Experience
Efficacy & Safety
Efficacy & Safety
Once-Weekly Prophylaxis
On-Demand Bleed Control
Surgical Efficacy
Support & Resources
Support & Resources
Events
Materials
Videos
Resources for Patients and Caregivers
Additional Resources
In a subset analysis, 95.5% of responses were rated excellent or good in both PTPs and PUPs receiving BeneFIX and undergoing surgery2
|
Surgical management rating scale: Efficacy was graded by subjective assessment of response to surgery by the subject and by the physician, in consultation with the surgeon. The response was rated excellent if the response was as satisfactory, with as much and as rapid an improvement as the best responses with other rFIX products for similar bleeds or procedures; good if the response was as satisfactory, with as much and as rapid an improvement as most responses with other rFIX products for similar bleeds or procedures; moderate if the response was less than satisfactory and not as good as most responses seen with other rFIX products when used for similar bleeding episodes or similar procedures; or no response if no improvement at all was observed.4,5
A 20-center international trial was conducted in PTPs with severe or moderate (<5 IU/dL FIX activity) hemophilia B. Participants received rFIX for pharmacokinetic studies, treatment of or prophylaxis against hemorrhage, or surgical hemostasis, and were assessed at 3-month intervals for 2 years.5
A multicenter, international, open-label, single-cohort study consisting of a core phase and an extension phase. In the core phase, patients received rFIX for (1) on-demand treatment in response to any bleeding episode, (2) routine prophylaxis, or (3) surgical prophylaxis. Patients who completed the core phase were allowed to enter the extension phase to receive rFIX for up to 1 additional year, at the discretion of the investigator and after prior written authorization from the sponsor.2,4
†In the PTP surgery subjects, the median increase in circulating FIX activity was 0.7 IU/dL per IU/kg infused (range 0.3-1.2 IU/dL; mean 0.8 ± 0.2 IU/dL per IU/kg).2
‡In the PUP surgery subjects, the mean dose per infusion was 89.87 ± 51.95 IU/kg, and mean duration of treatment was 5.09 ± 3.96 days.4
BeneFIX is available in hundreds of institutions nationwide.6 |
---|
Learn how you can personalize your patients’ dosing.
** This is an optional area where footnotes can live.
BeneFIX, Coagulation Factor IX (Recombinant), is a human blood coagulation factor indicated in adults and children with hemophilia B (congenital factor IX deficiency or Christmas disease) for the on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.
Limitation of use:
BeneFIX is not indicated for induction of immune tolerance in patients with hemophilia B.
Please see full Prescribing Information for BeneFIX.
BeneFIX, Coagulation Factor IX (Recombinant), is a human blood coagulation factor indicated in adults and children with hemophilia B (congenital factor IX deficiency or Christmas disease) for the on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.
Limitation of use:
BeneFIX is not indicated for induction of immune tolerance in patients with hemophilia B.
Please see full Prescribing Information for BeneFIX.
Please see full Prescribing Information.
OK. We'll need you to sign in before we can determine if you are aligned with a sales representative.
If you select 'Yes', you will be required to enter your username and password in the sign-in form that will appear over this window.
Would you like to sign in now?